Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: An open label trial [7]

Annals of the Rheumatic Diseases

Volumn 65, Issue 3, 2006, Pages 417-418

  Tam, L S ^a   Li, E K ^a   Wong, C K ^a   Lam, C W K ^a   Li, W C ^a   Szeto, C C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

LEFLUNOMIDE;

CHRONICITY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LABORATORY TEST; LETTER; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL;

ADULT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33144490424     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.044248     Document Type: Letter

References (2)

1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
2. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.